ArticleRomanian journal of ophthalmology
Anatomical and functional results of plasma rich in growth factors as a treatment for poor-prognosis macular holes.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The management of poor-prognosis full-thickness macular holes (FTMH), considered as large, myopic, recurrent, or persistent, is challenging, and there is no consensus on the most suitable option. Plasma rich in growth factors (PRGF) is a subtype of platelet-rich plasma with a higher concentration of growth factors, which promotes Müller cell proliferation and, therefore, closure of FTMH. This study aims to analyze the benefits of injectable plasma rich in growth factors (iPRGF) as an adjuvant to PPV in poor-prognosis FTMH. Materials and methods: A prospective, non-randomized study was conducted in patients with poor-prognosis FTMH. Patients were treated with PPV associated with adjuvant iPRGF. Postoperative best corrected visual acuity (BCVA), FTMH closure, retinal layer restoration, and type of closure were analyzed. Results: A total of 12 eyes were included in the study. Complete closure of the FTMH was achieved in 92% of the patients, and BCVA improvement in 75%. Reconstitution of the external retinal layers was observed in 41% of the patients, and closure type 1A in 41%. No adverse effects were recorded. Discussion: The high closure rate and visual improvement suggest that iPRGF is a promising adjuvant in poor-prognosis FTMH, likely through Müller cell stimulation and glial-mediated tissue repair. Compared with more complex techniques such as inverted ILM flaps or autologous retinal transplants, iPRGF offers a more straightforward, safer, and faster approach, particularly in myopic or recurrent cases. The potential synergistic effect of combining iPRGF with ILM flap techniques warrants further investigation. Conclusion: The use of iPRGF may be an effective technique for achieving anatomical closure, restoring retinal layers, and improving final BCVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.